Patents by Inventor Zachary Lattrell

Zachary Lattrell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OCULAR HYDROGEL TYROSINE KINASE INHIBITOR IMPLANTS
    Publication number: 20240285518
    Abstract: Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.
    Type: Application
    Filed: February 21, 2024
    Publication date: August 29, 2024
    Inventors: Peter Jarrett, Rami El-Hayek, Timothy S. Jarrett, Zachary Lattrell, Arthur Driscoll, Charles D. Blizzard
  • OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT
    Publication number: 20230390189
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 7, 2023
    Inventors: Charles D. BLIZZARD, Arthur DRISCOLL, Rami EL-HAYEK, Michael GOLDSTEIN, Joseph IACONA, Peter JARRETT, Timothy S. JARRETT, Erica KAHN, Zachary LATTRELL
  • OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT
    Publication number: 20230285282
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Application
    Filed: March 14, 2023
    Publication date: September 14, 2023
    Inventors: Charles D. BLIZZARD, Arthur DRISCOLL, Rami EL-HAYEK, Michael GOLDSTEIN, Joseph IACONA, Peter JARRETT, Timothy S. JARRETT, Erica KAHN, Zachary LATTRELL
  • OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR
    Publication number: 20230118774
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Application
    Filed: November 21, 2022
    Publication date: April 20, 2023
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • OCULAR HYDROGEL TYROSINE KINASE INHIBITOR IMPLANTS
    Publication number: 20230040637
    Abstract: Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.
    Type: Application
    Filed: August 3, 2022
    Publication date: February 9, 2023
    Inventors: Peter Jarrett, Rami El-Hayek, Timothy S. Jarrett, Zachary Lattrell, Arthur Driscoll, Charles D. Blizzard
  • Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor
    Patent number: 11534396
    Abstract: This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: December 27, 2022
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR
    Publication number: 20220347094
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 3, 2022
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • Ocular implant containing a tyrosine kinase inhibitor
    Patent number: 11439592
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: September 13, 2022
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR
    Publication number: 20220079876
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Application
    Filed: March 24, 2021
    Publication date: March 17, 2022
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR
    Publication number: 20210308043
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Application
    Filed: March 24, 2021
    Publication date: October 7, 2021
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • OCULAR HYDROGEL TYROSINE KINASE INHIBITOR IMPLANTS
    Publication number: 20200337989
    Abstract: Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 29, 2020
    Inventors: Peter Jarrett, Rami El-Hayek, Timothy S. Jarrett, Zachary Lattrell, Arthur Driscoll, Charles D. Blizzard